When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendations

HPB

Volumn 17, Issue 1, 2015, Pages 17-22

  Lesurtel, Mickaël ^a   Nagorney, David M ^b   Mazzaferro, Vincenzo ^c   Jensen, Robert T ^d   Poston, Graeme J ^e  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Mayo Clinic College of Medicine   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; HUMAN; LIVER METASTASIS; LIVER RESECTION; METASTASIS RESECTION; NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; TUMOR ABLATION; ADVERSE EFFECTS; CARCINOMA, NEUROENDOCRINE; CONSENSUS DEVELOPMENT; LIVER NEOPLASMS; MORTALITY; PATIENT SELECTION; RISK ASSESSMENT; RISK FACTOR; SECONDARY; STANDARDS; TIME FACTOR; TREATMENT OUTCOME;

CARCINOMA, NEUROENDOCRINE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; NEOPLASM STAGING; PATIENT SELECTION; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84915757943     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/hpb.12225     Document Type: Review

References (47)

1. Frilling A, Sotiropoulos GC, Li J, Kornasiewicz O, Plöckinger U,. (2010) Multimodal management of neuroendocrine liver metastases. HPB 12: 361-379.
2. Gurusamy KS, Ramamoorthy R, Sharma D, Davidson BR,. (2009) Liver resection versus other treatments for neuroendocrine tumours in patients with resectable liver metastases. Cochrane Database Syst Rev [Review]:(2) CD007060.
3. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9: 61-72.
4. Pavel M, Baudin E, Couvelard A, Krenning E, Oberg K, Steinmuller T, et al. (2012) ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95: 157-176.
5. Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, et al. (2005) Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104: 1590-1602.
6. Roche A, Girish BV, de Baere T, Baudin E, Boige V, Elias D, et al. (2003) Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol [Clinical Trial] 13: 136-140.
7. Que FG, Nagorney DM, Batts KP, Linz LJ, Kvols LK,. (1995) Hepatic resection for metastatic neuroendocrine carcinomas. Am J Surg 169: 36-42. discussion 43.
8. Guyatt GH, Oxman AD, Schunemann HJ, Tugwell P, Knottnerus A,. (2011) GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol 64: 380-382.
9. Kalt N, Haueis S, Poston G, Nagorney DM, Mazzaferro V, Jensen R, et al. PROSPERO CRD42012002652. 2012; Available from: http://www.crd.york.ac.uk/prospero/display-record.asp?ID=CRD42012002652. Archived at: http://www.webcitation.org/6LQUqMnqL.
10. Stump R, Haueis S, Kalt N, Tschuor C, Limani P, Raptis D, et al. (2013) Transplant and surgical strategies in patients with neuroendocrine liver metastases: protocol of four systematic reviews. JMIR Res Protoc 23; 2: e58.
11. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, et al. (2000) Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 190: 432-445.
12. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA,. (1998) Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg [Comparative Study] 187: 88-92. discussion -3.
13. Karabulut K, Akyildiz HY, Lance C, Aucejo F, McLennan G, Agcaoglu O, et al. (2011) Multimodality treatment of neuroendocrine liver metastases. Surgery 150: 316-325.
14. Landry CS, Scoggins CR, McMasters KM, Martin RCG, 2nd,. (2008) Management of hepatic metastasis of gastrointestinal carcinoid tumors. J Surg Oncol 97: 253-258.
15. Leblanc F, Fonck M, Brunet R, Becouarn Y, Mathoulin-Pelissier S, Evrard S,. (2008) Comparison of hepatic recurrences after resection or intraoperative radiofrequency ablation indicated by size and topographical characteristics of the metastases. Eur J Surg Oncol 34: 185-190.
16. Mayo SC, de Jong MC, Bloomston M, Pulitano C, Clary BM, Reddy SK, et al. (2011) Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol [Multicenter Study] 18: 3657-3665.
17. Musunuru S, Chen H, Rajpal S, Stephani N, McDermott JC, Holen K, et al. (2006) Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg 141: 1000-1004. discussion 1005.
18. Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, et al. (2006) Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. [Erratum appears in Ann Surg Oncol 2006;13:1162. Note: Strosberg, Jonathon [corrected to Strosberg, Jonathan]]. Ann Surg Oncol 13: 572-581.
19. Saxena A, Chua TC, Morris DL,. (2012) Liver-directed therapy as treatment of hepatic progression following surgical extirpation of neuroendocrine neoplasm hepatic metastasis. Ann Surg Oncol 18: S76.
20. Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, et al. (2005) Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 241: 776-783. discussion 83-5.
21. Yao KA, Talamonti MS, Nemcek A, Angelos P, Chrisman H, Skarda J, et al. (2001) Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery 130: 677-682. discussion 82-5.
22. Ahmed A, Turner G, King B, Jones L, Culliford D, McCance D, et al. (2009) Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study. Endocr Relat Cancer [Multicenter Study Research Support, Non-U.S. Gov't] 16: 885-894.
23. Dousset B, Saint-Marc O, Pitre J, Soubrane O, Houssin D, Chapuis Y,. (1996) Metastatic endocrine tumors: medical treatment, surgical resection, or liver transplantation. World J Surg 20: 908-914. discussion 14-5.
24. el Rassi ZS, Ferdinand L, Mohsine RM, Berger F, Lombard-Bohas C, Boillot O, et al. (2002) Primary and secondary liver endocrine tumors: clinical presentation, surgical approach and outcome. Hepatogastroenterology 49: 1340-1346.
25. Elias D, Goere D, Leroux G, Dromain C, Leboulleux S, de Baere T, et al. (2009) Combined liver surgery and RFA for patients with gastroenteropancreatic endocrine tumors presenting with more than 15 metastases to the liver. Eur J Surg Oncol 35: 1092-1097.
26. Elias D, Lasser P, Ducreux M, Duvillard P, Ouellet J-F, Dromain C, et al. (2003) Liver resection (and associated extrahepatic resections) for metastatic well-differentiated endocrine tumors: a 15-year single center prospective study. Surgery 133: 375-382.
27. Frilling A, Li J, Malamutmann E, Schmid KW, Bockisch A, Broelsch CE,. (2009) Treatment of liver metastases from neuroendocrine tumours in relation to the extent of hepatic disease. Br J Surg 96: 175-184.
28. Frilling A, Rogiers X, Malago M, Liedke OM, Kaun M, Broelsch CE,. (1998) Treatment of liver metastases in patients with neuroendocrine tumors. Langenbecks Arch Surg 383: 62-70.
29. Gaujoux S, Gonen M, Tang L, Klimstra D, Brennan MF, D'Angelica M, et al. (2012) Synchronous Resection of Primary and Liver Metastases for Neuroendocrine Tumors. Ann Surg Oncol 19: 4270-4277.
30. Glazer ES, Tseng JF, Al-Refaie W, Solorzano CC, Liu P, Willborn KA, et al. (2010) Long-term survival after surgical management of neuroendocrine hepatic metastases. HPB [Research Support, N.I.H., Extramural] 12: 427-433.
31. Gomez D, Malik HZ, Al-Mukthar A, Menon KV, Toogood GJ, Lodge JPA, et al. (2007) Hepatic resection for metastatic gastrointestinal and pancreatic neuroendocrine tumours: outcome and prognostic predictors. HPB 9: 345-351.
32. Grazi GL, Cescon M, Pierangeli F, Ercolani G, Gardini A, Cavallari A, et al. (2000) Highly aggressive policy of hepatic resections for neuroendocrine liver metastases. Hepatogastroenterology 47: 481-486.
33. Hibi T, Sano T, Sakamoto Y, Takahashi Y, Uemura N, Ojima H, et al. (2007) Surgery for hepatic neuroendocrine tumors: a single institutional experience in Japan. Jpn J Clin Oncol 37: 102-107.
34. House MG, Cameron JL, Lillemoe KD, Schulick RD, Choti MA, Hansel DE, et al. (2006) Differences in survival for patients with resectable versus unresectable metastases from pancreatic islet cell cancer. J Gastrointest Surg [Comparative Study] 10: 138-145.
35. Kianmanesh R, Sauvanet A, Hentic O, Couvelard A, Levy P, Vilgrain V, et al. (2008) Two-step surgery for synchronous bilobar liver metastases from digestive endocrine tumors: a safe approach for radical resection. Ann Surg 247: 659-665.
36. Knox CD, Feurer ID, Wise PE, Lamps LW, Kelly Wright J, Chari RS, et al. (2004) Survival and functional quality of life after resection for hepatic carcinoid metastasis. J Gastrointest Surg 8: 653-659.
37. Mayo SC, de Jong MC, Pulitano C, Clary BM, Reddy SK, Gamblin TC, et al. (2010) Surgical management of hepatic neuroendocrine tumor metastasis: results from an international multi-institutional analysis. Ann Surg Oncol [Multicenter Study] 17: 3129-3136.
38. Nave H, Mossinger E, Feist H, Lang H, Raab H,. (2001) Surgery as primary treatment in patients with liver metastases from carcinoid tumors: a retrospective, unicentric study over 13 years. Surgery [Evaluation Studies] 129: 170-175.
39. Norton JA, Warren RS, Kelly MG, Zuraek MB, Jensen RT,. (2003) Aggressive surgery for metastatic liver neuroendocrine tumors. Surgery 134: 1057-1063. discussion 63-5.
40. Pascher A, Steinmuller T, Radke C, Hosten N, Wiedenmann B, Neuhaus P, et al. (2000) Primary and secondary hepatic manifestation of neuroendocrine tumors. Langenbecks Arch Surg 385: 265-270.
41. Roth T, Marmorale A, Gavelli A, Huguet C,. (2002) [The surgical treatment of liver metastasis of carcinoid tumors]. Ann Chir [Case Reports English Abstract] 127: 783-785.
42. Sarmiento JM, Heywood G, Rubin J, Ilstrup DM, Nagorney DM, Que FG,. (2003) Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival. J Am Coll Surg 197: 29-37.
43. Sarmiento JM, Que FG, Grant CS, Thompson GB, Farnell MB, Nagorney DM,. (2002) Concurrent resections of pancreatic islet cell cancers with synchronous hepatic metastases: outcomes of an aggressive approach. Surgery 132: 976-982.
44. Saxena A, Chua TC, Chu F, Al-Zahrani A, Morris DL,. (2012) Optimizing the surgical effort in patients with advanced neuroendocrine neoplasm hepatic metastases: a critical analysis of 40 patients treated by hepatic resection and cryoablation. Am J Clin Oncol 35: 439-445.
45. Saxena A, Chua TC, Chu FC, Liauw W, Morris DL,. (2011) Progression and survival results after radical hepatic metastasectomy of advanced neuroendocrine neoplasms (NENS) supports an aggressive surgical approach. Surgery 149: 209-220.
46. Sporn E, Mancini GJ, Khajanchee Y, Wilson C, Hansen PD, Swanstrom LL, et al. (2008) Multimodal cytoreduction for carcinoid liver metastases: analysis of a case series with highly advanced disease. Eur Surg Acta Chir Austriaca 40: 72-76.
47. Strosberg J, Gardner N, Kvols L,. (2009) Survival and prognostic factor analysis of 146 metastatic neuroendocrine tumors of the mid-gut. Neuroendocrinology 89: 471-476.